Key facts
- It has raised $9.0M; the latest was Later Stage VC ($3.5M) in Jan 2026.
- Notable investors include High-Tech Gründerfonds, Novalis Biotech, OCCIDENT (), Ostwerk, Saxonia Holding — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Altavo
- ·The full record, as it builds
Funding rounds
No funding rounds for Altavo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Altavo
Developer of a non-invasive medical speech device designed for vocal rehabilitation purposes. The company's platform utilizes high-frequency radar sensors and artificial intelligence to detect articulatory movements of the tongue and lips, converting these silent signals into a personalized, natural-sounding digital voice in real time, enabling patients with speech impairments to communicate.
- Sector
- Healthcare
- HQ
- Dresden, Germany
- Founded
- 2021
- Employees
- 16
- Website
- altavo.eu/
- Ownership
- Privately Held (backing)
Altavo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Altavo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Altavo in its N-PORT filings yet. We sweep new filings monthly.